Publikasi Scopus 2010 s/d 2022

Authors_(Last_Name)

Waleleng B.J., Adiwinata R., Wenas N.T., Haroen H., Rotty L., Gosal F., Rotty L., Winarta J., Waleleng A., Simadibrata M.

Author S Id

57218497570;57190987165;57220780697;55257490600;55257626400;57218498488;57310038200;57218497057;57218497568;23499598400;

Title

Screening of pancreatic cancer: Target population, optimal timing and how?

Year

2022

Source Title

Annals of Medicine and Surgery

Volume

Issue

Art No

104814

Page Start

Page End

Page Count

Cited By

Link

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141469607&doi=10.1016%2fj.amsu.2022.104814&partnerID=40&md5=575c4c58b510d7af475cfef2a8f4b3f0

Affiliations

Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Division of Gastroenterology, Pancreatobiliary and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia

Authors With Affiliations

Waleleng, B.J., Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Adiwinata, R., Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Wenas, N.T., Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Haroen, H., Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Rotty, L., Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Gosal, F., Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Rotty, L., Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Winarta, J., Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Waleleng, A., Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi/Prof. dr. R. D. Kandou Hospital, Manado, Indonesia; Simadibrata, M., Division of Gastroenterology, Pancreatobiliary and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia

Abstract

Pancreatic cancer patients usually present at a late stage due to subtle clinical manifestations. One of the most predictive prognostic factors in pancreatic cancer is the pancreatic cancer stage at diagnosis; therefore, early diagnosis is essential. Until now, pancreatic cancer screening has not become a standard practice for the general population due to the low incidence. In current circumstances, targeting individuals with a high risk of pancreatic cancer may be more rational. Several screening modalities for pancreatic cancer have also become debatable topics. Therefore, this article will review current evidence and recommendations regarding pancreatic screening cancer protocol in general and in high-risk populations. © 2022 The Authors

Author Keywords

Diagnosis; Pancreas; Pancreatic cancer; Screening

Index Keywords

apoptosis; ataxia telangiectasia; cancer mortality; cancer patient; cancer prognosis; cancer screening; cancer susceptibility; early diagnosis; genetic disorder; genetic risk; genetic screening; high risk population; human; Li-Fraumeni syndrome; melanoma; ovary cancer; overall survival; pancreas cancer; Review; risk factor

Funding Details

Funding Text 1

The previous findings influence the determination of screening intervals during screening. International Cancer of the Pancreas Screening Consortium recommends a 12-month screening interval in high-risk patients if no abnormalities or non-concerning abnormalities are found. Screening every 3–6 months was recommended for high-risk individuals with newly detected pancreatic cancer, but this did not

Funding Text 2

Funding Text 3

Publisher

Elsevier Ltd

Issn

20490801

Isbn

Pubmed Id

Document Type

Review

Sjr Best Quartile

Sjr

373

Sjr Rank

12721